Srinivas Sandy, Krishnan Aruna V, Colocci Natalia, Feldman David
Division of Oncology, Stanford University School of Medicine, Stanford, California 94305, USA.
Urology. 2006 May;67(5):1001-6. doi: 10.1016/j.urology.2005.11.004.
To assess the effect of triamcinolone administration on the serum prostate-specific antigen (PSA) response and the time to progression in patients with androgen-independent prostate cancer (AIPC).
Patients with AIPC were prospectively treated with oral triamcinolone 4 mg twice daily, and their serum PSA and cortisol levels were measured monthly. Patients with greater than 25% increases in serum PSA from baseline were considered to have progressive disease and were removed from the study. Those patients who had a decrease in serum PSA levels or stable disease continued in the study until disease progression. Bone scans were obtained every 12 weeks and at progression.
Twenty-four patients with AIPC were treated from November 2002 to June 2004. A partial response with a more than 50% decrease in serum PSA level was seen in 29%. Another 21% achieved stable disease. No statistically significant difference was found in the time to progression in the partial responders and patients with stable disease. The median time to progression in both groups was 7.5 months. Treatment was well tolerated without any grade 3 or 4 toxicity.
Oral triamcinolone was well tolerated by patients with AIPC, with 50% of the patients exhibiting a good response to therapy in terms of serum PSA level and time to progression.
评估曲安奈德给药对去势抵抗性前列腺癌（AIPC）患者血清前列腺特异性抗原（PSA）反应及疾病进展时间的影响。
对AIPC患者进行前瞻性治疗，口服曲安奈德4毫克，每日两次，每月测量血清PSA和皮质醇水平。血清PSA较基线水平升高超过25%的患者被视为疾病进展，退出研究。血清PSA水平下降或病情稳定的患者继续留在研究中，直至疾病进展。每12周及疾病进展时进行骨扫描。
2002年11月至2004年6月，对24例AIPC患者进行了治疗。29%的患者出现部分缓解，血清PSA水平下降超过50%。另外21%的患者病情稳定。部分缓解者和病情稳定患者的疾病进展时间无统计学显著差异。两组的中位疾病进展时间均为7.5个月。治疗耐受性良好，无3级或4级毒性。
AIPC患者对口服曲安奈德耐受性良好，50%的患者在血清PSA水平和疾病进展时间方面对治疗表现出良好反应。
